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association with productivity measures. METHODS: A cross-sectional survey of 
adults diagnosed with T2DM on OADs, and not insulin, was conducted. A list of 
common tolerability issues from OAD prescribing information was provided; experi-
ence with each was asked in the survey. The Diabetes Productivity Measure (DPM)
and the Work Productivity and Activity Impairment (WPAI) measure work productiv-
ity. Chi-square tests were done for categorical variables and t-tests for continuous 
variables. Linear-regression methods were used to control for respondent characteris-
tics. RESULTS: Of 2,074 survey respondents, 53% were men and mean age was 
60 yrs (SD  10.83). In the 2 wks preceding the survey, 70.5% experienced at least
one tolerability issue. The most commonly reported issues were hypoglycemia (57.2%,
q1 symptom), constipation or diarrhea (28%), headaches (26%), and water retention
(21%). In most cases, a reduction in work productivity of 8% to 24%, mainly impair-
ing work presenteeism, was observed with tolerability issues reported in the previous
two weeks (WPAI: p  0.05). After adjusting for characteristics, signiﬁ cant reductions 
on productivity, measured by DPM and WPAI (p  0.05), were observed for hypogly-
cemia (9.7% to 10.6%), unintended weight loss (11.1% to 14.4%), water reten-
tion (3.6% to 4.9%), constipation or diarrhea (2.8% to 4.2%) and urinary 
tract infection (13.5% to 16.8%). Cardiovascular events were signiﬁ cant (67%,
p  0.05) with WPAI, but not DPM; nausea/vomiting, headache, genital infections, 
and appetite loss were not signiﬁ cant. CONCLUSIONS: T2DM patients reported a
high level of tolerability issues and diabetes symptoms associated with decreased work 
productivity. This study highlights the importance of addressing tolerability issues and 
symptoms to reduce overall disease burden.
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OBJECTIVES: A considerable amount of the investigation of geographic variation 
focuses on Medicare data and excludes prescription drugs. This study focuses on pre-
scription medications used to treat chronic conditions in the commercial sector and
incorporates demand-side information on insurance beneﬁ t design (e.g., patient cost-
sharing) to analyze variations in adherence. METHODS: Patients age 18–64 in
employer-sponsored plans with at least two years of continuous medical and prescrip-
tion coverage meeting diagnostic criteria for diabetes were found in the MarketScan 
Database (n  449,127). Medication Possession Ratios (MPRs) were calculated in
2006 and 2007 for four classes of medications (antidiabetic medications, statins, ACE 
Inhibitors, Angiotensin II Receptor Blockers (ARB)) for each patient with at least 
one prescription within the class each year. Multivariate logistic regressions of poor 
adherence (MPR  80%) were estimated to adjust for patient, employer, beneﬁ t plan, 
provider supply, and area (e.g., income, unemployment) characteristics. Expected 
adherence based on predicted values from the multivariate regressions was aggregated 
to the geographic area (hospital referral region, HRR) level and the ratio of observed 
to expected adherence was computed along with the 95% conﬁ dence interval of the
ratio. RESULTS: Across HRRs the median rate of subobtimal antidiabetic medication 
adherence was 32.3% of patients, rates in HRRs varied from 19.2% to 54.6%. The 
median rate was 44% for ACE Inhibitors (range 30.2% to 60.4%), 43.9% for ARBs
(range 27.5% to 60.7%) and 59.3% for statins (range 45% to 74.5%). The difference 
between observed and expected adherence was statistically signiﬁ cant for 8.9% of 
HRRs for antidiabetic medication, 9.1% of HRRs for ACE Inhibitors, 6.7% of HRRs 
for ARBs and 1.3% of HRRs for statins (p  0.05). CONCLUSIONS: Observed
market level traits such as provider supply and unemployment explain some of the 
variation in adherence. After adjusting for covariates, geographic variation in chronic
condition medication utilization remains.
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OBJECTIVES: A randomized controlled study is being conducted to evaluate 2 types
of educational interventions (groups using Conversation Maps, versus individual)
compared to usual care (no educational intervention) for patients with pre-existing
type-2 diabetes and suboptimal glycemic control (A1c  7%). The purpose is to 
determine if there are correlations at baseline with patient Readiness to Change (RTC) 
and attitudes toward diabetes, and measures of general health and diabetes control. 
METHODS: At baseline, 167 female and 172 male patients (mean age 63 years, mean
A1c 8.1) enrolled in the Merck-funded Journey for Control of Diabetes IDEA Study 
and completed a baseline survey. Validated instruments embedded in the survey were:
RTC (O’Connor et al, 2004), functional health status (SF-12), attitude towards dia-
betes (positive attitude and care ability scales, sections of the Diabetes Care Proﬁ le
from Michigan Diabetes Research and Training Center). Also, the most recent A1c 
result within the last six months and length of time diagnosed with diabetes were
obtained. RESULTS: Pearson correlations were used to assess associations between
RTC and general health, diabetes attitudes, and measures of diabetes control. Mean 
RTC scores were 24.02 (range 7 – 38; n  320), with females slightly more ready to 
change than males (p  0.0924). RTC had a signiﬁ cant positive correlation with 
A1c (r  0.1096, p  0.0500), with both the number of reported hypoglycemic events 
(r  0.16217, p  0.0037) and hyperglycemic events (r  0.13854, p  0.0133). RTC 
was also signiﬁ cantly correlated with Positive Attitudes toward diabetes (r  0.11415, 
p  0.0433). Interestingly, RTC was not related to functional health (r  0.10964, 
p  0.7167). CONCLUSIONS: RTC is a useful tool to identify the potential success
for diabetes education. Additional validation of this ﬁ nding will be available upon the 
conclusion of the study.
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OBJECTIVES: To determine diabetes control status among community pharmacy
users with diabetes. METHODS: This is a cross-sectional observational study analyz-
ing the Medical Expenditure Panel Survey (2005), a survey nationally representative 
of non-institutionalized civilians. The study population was community pharmacy
users older than 17 with diabetes. Using a chi-square test, this study compared the 
proportions of the study population with complications and without complications 
meeting the diabetes control standards of the American Diabetes Association (ADA).
A logistic regression was employed to compare between the 2 groups the likelihood
of incurring drug costs over $4000 in 2006 dollars, the cost criterion for being eligible 
for mediation therapy management (MTM) services. Community pharmacies were 
deﬁ ned as pharmacies other than mail-order and online pharmacies. RESULTS: In 
2005, 95.27% of patients with diabetes ﬁ lled prescriptions through community phar-
macies. There were gaps between their diabetic control and the ADA standards, espe-
cially in the use of preventive services: e.g., ADA recommends weight control, but the
proportions of overweight or obese were 84.09% and 89.42% among patients without 
complications and those with complications, respectively (P  0.312 for the group
comparison). Patients with complications have higher likelihood of meeting the cost
criterion for MTM services even after adjusting for confounding factors (P  0.005). 
CONCLUSIONS: The room for improvements in diabetes control among community 
pharmacy users in this study present pharmacists with opportunities for improving
diabetes management.
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OBJECTIVES: To describe the relationship between A1c levels and medication
possession ratio (MPR) of three oral anti-hyperglycemic medications (sulfonylureas,
biguanides and thiazolidinediones) for participants enrolled in a diabetes disease 
management program. METHODS: This was a retrospective evaluation of partici-
pants enrolled in a diabetes disease management program. Continuously enrolled
participants were included if there was a documented A1c value. The MPR was cal-
culated from administrative pharmacy claims data. Participants were classiﬁ ed as low, 
moderate or high risk based on their A1c levels. ANOVA was used to analyze differ-
ences in mean MPR between the three groups. For participants on more than one drug
class, a Pearson’s correlation was used to analyze relationship of MPRs between dif-
ferent drug classes. RESULTS: A total of 57 percent of participants on sulfonylurea
therapy, 64 percent of participants on biguanides and 63 percent of those on thiazoli-
dinediones reached an A1c goal of 7. Participants classiﬁ ed as high risk (A1c  9) 
had a lower MPR compared to participants in the low and moderate risk group (p 
0.0001). For participants taking a sulfonylurea, the mean MPR for those who reached 
the predetermined A1c goal (7) was 0.89 (o0.21) compared with 0.76 (o0.30) for 
those in the high risk group (p  0.001). MPR for thiazolidinediones was 15 percent 
lower in participants with A1c  9 (p  0.001). Pearson correlation analysis showed 
a positive relationship between the MPRs in different drug classes. CONCLUSIONS:
Medication adherence as measured by the MPR was higher for participants who
reached the target A1c goal of 7.
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OBJECTIVES: Tight glycemic control of diabetic patients yields both clinical and 
ﬁ nancial beneﬁ ts. Despite recommendations for HbA1C testing to assess the effective-
ness of management plans on glycemic control, achieving adherence to recommenda-
tions for frequency of HbA1C testing continues to be a challenge. When prior 
authorization (PA) was required in the Leumit Health Fund of Israel for expensive
diabetes medications, requests for these drugs were not reviewed until the patient had
performed an HbA1C test (one test within the previous four months). This policy 
induced complete adherence to recommendations for testing amongst patients treated
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with target drugs. The purpose of this study was to ascertain whether revocation of 
the PA requirement resulted in inferior rates of HbA1C testing amongst new users of 
these drugs. METHODS: Data on of new users of the target drugs and on HbA1C
testing in these patients was extracted from EPR databases for the six-month post-
revocation period. The proportion of patients who performed at least one HbA1C test 
during the four months prior to initiation of treatment and 95% conﬁ dence intervals 
were calculated. The data were stratiﬁ ed by month to detect possible trends in rates
of testing during the post policy-change period. RESULTS: After rescinding the PA 
requirement, HbA1C testing amongst incident users of the target drugs dropped from
100% during the PA period to rates of 85.6% (95% CI  79.7, 91.5) to 94.4% (95%
CI  90.8, 97.9). Statistically signiﬁ cant variance in monthly rates of testing was not
observed. CONCLUSIONS: The PA requirement resulted in total performance of a
lab test necessary to monitor drug-therapy outcomes in diabetic patients. When PA is 
implemented as a quality-assurance strategy, revocation should be accompanied by
continuing-education efforts to maintain adherence to recommendations for appropri-
ate care.
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OBJECTIVES: To measure the impact of pharmacist-provided diabetes management 
program on the economic, clinical, and humanistic outcomes for the City of Toledo
employees and their dependents for a period of 6 months. METHODS: This is a pro-
spective, pre-post longitudinal study. Clinical outcomes collected were A1c, blood
pressure (BP), and body mass index (BMI). These outcomes were measured at the 
baseline, 3 and 6 month visits. Economic outcomes include cost of physician ofﬁ ce
visits, emergency room visits, and inpatients days. These outcomes were measured at 
baseline and 6 month visits. Humanistic outcomes collected were quality of life (using
Sf36v2), patient satisfaction, adherence with medications, and knowledge about dia-
betes. The quality of life and knowledge about diabetes were measured at baseline
and 6 month visits. The patient satisfaction and adherence with medications (using
Morisky scale) were measured at baseline and 3 months visits. Wilcoxon-Signed rank 
test was used to compare variables at two time points. Friedman test was used to
compare variables at multiple time points. Preliminary data analysis for the period 
between baseline visit to 3 months visit is given below. RESULTS: Ninty ﬁ ve patients
have been enrolled to date. Mean A1c’s have decreased signiﬁ cantly from 7.78 at 
baseline visit to 7.44 at 3 months (p  0.05) (N  59). For Intention to treat population 
(baseline A1C  7), the decrease in A1c is even more signiﬁ cant (p  0.01) (N  33). 
Diastolic blood pressure has decreased signiﬁ cantly (p  .001) while systolic blood
pressure and BMI have decreased non-signiﬁ cantly. Self monitoring of blood glucose 
has increased signiﬁ cantly (p  0.01). Patient satisfaction and adherence with medica-
tions has also improved signiﬁ cantly at three-month follow-up visit (p  0.05). Final 
results for the period between baseline visit to 6 months including economic outcomes
will be presented at the ISPOR 14th Annual International Meeting. CONCLUSIONS:
Preliminary data analysis showed that pharmacists can improve the clinical outcomes
in patients with diabetes.
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OBJECTIVES: This study examined changes in opioid medication utilization follow-
ing treatment for diabetic peripheral neuropathic pain (DPNP). METHODS: We
studied commercially insured individuals aged 18–64 years who were dispensed dulox-
etine or other DPNP standard of care (SOC) medications (i.e. escitalopram, venlafax-
ine, gabapentin, amitriptyline, or pregabalin) between March 1, 2005 and December 
31, 2005. The dispense date of the initial agent was denoted as the “index date.” 
Patients included were diagnosed with DPNP in the 1 year prior to index and received 
opioids in the prior 90 days. “Duloxetine” and “SOC” cohorts were constructed based
on index agent. Patients in the duloxetine cohort were required to be “continuous” 
users (medication possession ratio q0.8). We assessed changes in long-acting (LA) and
short-acting (SA) opioid utilization one year before and after the index date. Multivari-
ate linear regressions were performed to control for differences in patient demographic 
and clinical characteristics between study cohorts. RESULTS: We identiﬁ ed 97 dulox-
etine patients and 943 SOC patients. Study cohorts were similar in age (mean  55 
years) and proportion female (53%). Over 87% and 20% patients in each cohort were 
dispensed an SA and LA opioid in both the pre- and post-index periods, respectively. 
Hydrocodone was the most common SA opioid, followed by propoxyphene. Oxyco-
done and tramadol were the most common LA opioids. Compared to SOC patients,
continuous duloxetine patients had a greater reduction in days on SA hydrocodone 
(25.8 days, p  0.05), number of SA hydrocodone prescriptions (1.4, p  0.05), and 
days on DPNP-related SA opioids (15.5, p  0.09). Continuous duloxetine users also 
had greater reduction in days on LA oxycodone compared with the SOC patients (8.9, 
p  0.05). CONCLUSIONS: These ﬁ ndings among DPNP patients indicate that con-
tinuous duloxetine users were more likely to have a reduction in use of SA opioids 
and LA oxycodone versus SOC patients.
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OBJECTIVES: The impact of various medical insurance structures on the quality of 
care is not clearly understood. Drug utilizations patterns of type 2 diabetes patients 
may be affected by health care access, which vary across various types of health insur-
ance and may lead to disparities in disease control and clinical results. METHODS:
A cross-sectional analysis was conducted on data from the National Health and Nutri-
tion Examination Survey (NHANES) 2005–2006. Based on data from survey, patients 
aged 20 years and older with diagnosed type 2 diabetes were classiﬁ ed as patients with
commercial insurance, Medicare and/or Medigap, Medicaid, multiple insurance, other
types of insurance and no health insurance coverage. Likelihood of oral anti-diabetic
medications, insulin or combinations and the likelihood of having successful Glycemic
control were modeled with multi-variables logistic regression analyses with adjustment 
for age, gender, BMI, ethnicity, diabetic complications, household incomes and impor-
tant co-morbidities. RESULTS: A total of 403 diabetic patients were included in the 
analysis. Compared to commercially-insured patients, patients under Medicare (OR 
1.36, 95% CI  0.62, 3.00) or Medicaid (OR  2.32, 95% CI  0.76, 7.04) were more 
likely to be treated with insulin, but less likely to receive oral anti-diabetic medications
(OR  0.19, 95% CI  0.09, 0.40 for Medicare; OR  0.19, 95% CI  0.07, 0.51 for 
Medicaid). The likelihood of having successful glucose control varied but was not
signiﬁ cantly different across types of plans (P  0.05). CONCLUSIONS: Treatment 
patterns varied across various types of health insurance plans and might have impact
on the optimum quality of care and expenditure implications.
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OBJECTIVES: To evaluate the impact of value-based insurance design (VBID) on 
adherence to diabetic medications. METHODS: Health Alliance Medical Plans of 
Illinois piloted VBID by placing at least one diabetic drug in each class at Tier 1 with 
a $10 copayment for a subgroup of 5400 enrollees in January 2007, while keeping
drug beneﬁ ts unchanged for all other plan enrollees. A matched difference in difference 
method (DID) was used to evaluate the effect of VBID, based on pharmacy claim data. 
Patients with unchanged beneﬁ ts in the same plan were used as the control group.
Patients included in the analysis needed to be continuously enrolled from January
2006 to December 2007 and have used diabetic medications in both years. Adherence
was measured by the proportion of days covered (PDC). A logistic model was used
to model the probability of having PDC  0.8. A 1-to-1 matched control group was 
generated based on propensity score. RESULTS: There were 71 patients in the case
group and 5037 patients in the control group. The matched control group had 71
patients with similar propensity score, baseline characteristics and baseline adherence 
level with the case group. After the implementation of VBID, the average copayment
for diabetic medications decreased from $21.70 to $14.00 for the case group and 
increased from $19.60 to $22.00 for the matched control group. The probability of 
being adherent increased from 69% to 79% for the case group and decreased from
72% to 70% for the matched control group. The matched DID model showed that 
VBID increased the probability of being adherent: OR  1.84, 95% CI: 0.96–3.54, 
p  0.068. The full sample DID estimated OR  1.56 with p  0.065. CONCLUSIONS:
A VBID program that reduced the copayment for diabetic medications by 35%
improved the odds of adherence by 84% and reduced the number of non-adherent
patients by 35%.
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OBJECTIVES: To examine the association between medication adherence and poten-
tially avoidable hospitalizations (PAHs) among Medicare part D enrollees with dia-
betes. METHODS: A longitudinal retrospective cohort study of 493,609 Medicare 
part D enrollees with diabetes from 6 states (Alabama, California, Florida, Mississippi,
New York and Ohio) who had ﬁ lled at least 1 prescription for oral hypoglycemics, 
angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, and statins.
Adherence was calculated as proportion of days covered for all three classes of medica-
tions using Part D records for the ﬁ rst 6 months of 2006. A summary measure of 
adherence was computed for each patient as an ordinal variable – adherent to none,
any one class, any two classes and all three classes of medications. Medicare part A 
records for the next nine months were used to identify PAHs, as deﬁ ned by the
AHRQ’s Prevention Quality Indicators for diabetes care. Logistic regression was used
to assess the association between nonadherence and PAHs. RESULTS: A total of 
16.2%, 15.7%, 27.3% and 40.8% of patients were adherent with none, any one class, 
any 2 classes and all three classes of medications respectively. A total of 23,222 (4.7%)
patients had at least one PAH, 0.12% had an admission due to diabetes short-term
